An observational study in Mild Cognitive Impairment, sponsored by Eisai Korea Inc.. Completed at 16 sites in Korea, Republic of. Open to participants aged 55 Years to 89 Years. Per ClinicalTrials.gov, last updated 2021-10-06.
Sponsored by Eisai Korea Inc. · Observational
This study will be conducted to evaluate the rate of Alzheimer's disease conversion differences between high-risk mild cognitive impairment (MCI) and low-risk MCI.
Participants with mild cognitive impairment
Exclusion Criteria:
This cohort will include participants with high-risk mild cognitive impairment (MCI).
Other: Usual care setting
This cohort will include participants with low-risk MCI.
Other: Usual care setting
usual care settings without any intervention
Rate of Alzheimer's Disease (AD) conversion differences between high-risk mild cognitive impairment (MCI) and low-risk MCI
AD conversion differences will be assessed according to National Institute of Neurological and Communicative Diseases and Stroke-Alzheimer's Disease and Related Disorders Association Criteria for Probable AD.
Time frame: Up to 36 months
Mean change from Baseline in Seoul Neuropsychological Screening Battery-Dementia Version scores
Time frame: Baseline, Month 12, Month 24
Mean change from Baseline in Clinical Dementia Rating (CDR) Sum of Boxes scores
Time frame: Baseline, Month 12, Month 24
Mean change from Baseline in the CDR-Global Score
Time frame: Baseline, Month 12, Month 24
Mean change from Baseline in Geriatric Depression Scale scores
Time frame: Baseline, Month 12, Month 24
Mean change from Baseline in the volume of the whole brain according to Baseline demographics
Time frame: Baseline, Month 12, Month 24
Mean change from Baseline in other structural magnetic resonance imaging (MRI) measures according to Baseline demographics
Time frame: Baseline, Month 12, Month 24
Mean change from Baseline in the volume of the hippocampus according to Baseline demographics
Time frame: Baseline, Month 12, Month 24
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eisai Korea Inc.